Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study
Background Clinical data on patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant are limited, especially on clinical status after the application of antibody therapy. Methods We evaluated clinical status in patients with the SARS-CoV-2 delta variant after BRII-196 and BRII-198 treatment in an infectious disease hospital in China. We collected data on clinical symptoms, laboratory tests, radiological characteristics, viral load, anti-SARS-CoV-2 antibodies, treatment, and outcome. Results In mid-June 2021, 36 patients with delta variant infection were identified in Shenzhen. The most common symptoms at illness onset were cough (30.6%), fever (22.2%), myalgia (16.7%), and fatigue (16.7%). A small number of patients in this study had underlying diseases, including diabetes (5.6%) and hypertension (8.3%). The application of BRII-196 and BRII-198 can rapidly increase anti-SARS-CoV-2 IgG. The median peak IgG levels in the antibody treatment group were 32 times higher than those in the control group (P < 0.001). The time from admission to peak IgG levels in the antibody treatment group (mean: 10.2 days) was significantly shorter than that in the control group (mean: 17.7 days). Chest CT score dropped rapidly after antibody therapy, with a mean duration of 5.74 days from admission to peak levels. Conclusion The results of this study suggest that the application of BRII-196 and BRII-198 antibody therapy improved clinical status in patients with SARS-CoV-2 delta variant infection..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Virology journal - 19(2022), 1 vom: 15. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liao, Xuejiao [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Antibody therapy |
|---|
| Anmerkungen: |
© The Author(s) 2022 |
|---|
| doi: |
10.1186/s12985-022-01944-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR051238780 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR051238780 | ||
| 003 | DE-627 | ||
| 005 | 20230509122731.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230508s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12985-022-01944-6 |2 doi | |
| 035 | |a (DE-627)SPR051238780 | ||
| 035 | |a (SPR)s12985-022-01944-6-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liao, Xuejiao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Background Clinical data on patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant are limited, especially on clinical status after the application of antibody therapy. Methods We evaluated clinical status in patients with the SARS-CoV-2 delta variant after BRII-196 and BRII-198 treatment in an infectious disease hospital in China. We collected data on clinical symptoms, laboratory tests, radiological characteristics, viral load, anti-SARS-CoV-2 antibodies, treatment, and outcome. Results In mid-June 2021, 36 patients with delta variant infection were identified in Shenzhen. The most common symptoms at illness onset were cough (30.6%), fever (22.2%), myalgia (16.7%), and fatigue (16.7%). A small number of patients in this study had underlying diseases, including diabetes (5.6%) and hypertension (8.3%). The application of BRII-196 and BRII-198 can rapidly increase anti-SARS-CoV-2 IgG. The median peak IgG levels in the antibody treatment group were 32 times higher than those in the control group (P < 0.001). The time from admission to peak IgG levels in the antibody treatment group (mean: 10.2 days) was significantly shorter than that in the control group (mean: 17.7 days). Chest CT score dropped rapidly after antibody therapy, with a mean duration of 5.74 days from admission to peak levels. Conclusion The results of this study suggest that the application of BRII-196 and BRII-198 antibody therapy improved clinical status in patients with SARS-CoV-2 delta variant infection. | ||
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SARS-CoV-2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Antibody therapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Delta variant |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Clinical manifestation |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Li, Dapeng |4 aut | |
| 700 | 1 | |a Liu, Jie |4 aut | |
| 700 | 1 | |a Liu, Zhi |4 aut | |
| 700 | 1 | |a Ma, Zhenghua |4 aut | |
| 700 | 1 | |a Dong, Jingke |4 aut | |
| 700 | 1 | |a Yang, Xiangyi |4 aut | |
| 700 | 1 | |a Shu, Dan |4 aut | |
| 700 | 1 | |a Yuan, Jing |4 aut | |
| 700 | 1 | |a Liu, Lei |4 aut | |
| 700 | 1 | |a Zhang, Zheng |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Virology journal |d London : BioMed Central, 2004 |g 19(2022), 1 vom: 15. Dez. |w (DE-627)SPR029231027 |w (DE-600)2160640-7 |x 1743-422X |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2022 |g number:1 |g day:15 |g month:12 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12985-022-01944-6 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2022 |e 1 |b 15 |c 12 | ||